Avience Biomedicals Ltd

Avience Biomedi. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Avience Biomedicals Ltd

₹ 260 3.40%
24 Jul 3:40 p.m.
Company website NSE - SME: AVIENCE
About

Incorporated in June 2024, Avience Biomedicals Limited is an ISO certified company specializing in manufacturing, supplying, and exporting molecular diagnostic solutions.[1]

Key Points

Business Profile:[1]
Avience Biomedicals Limited, incorporated
during the COVID-19 pandemic, is a Noida
based manufacturer of In-Vitro Diagnostic
(IVD) products and medical devices, recognized as a Startup and Small-Scale Industry under MSME.

Website NSE - SM
  • Market Cap ₹ 142 Cr.
  • Current Price ₹ 260
  • High / Low ₹ 415 / 222
  • Stock P/E 16.3
  • Book Value ₹
  • Dividend Yield 0.00 %
  • ROCE 26.6 %
  • ROE 32.4 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company has a good return on equity (ROE) track record: 3 Years ROE 37.9%

Cons

  • Company might be capitalizing the interest cost

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Healthcare Equipment & Supplies Medical Equipment & Supplies

Edit Columns
Loading peers table ...

Half Yearly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2025 Sep 2025 Mar 2026
24.47 26.82 25.69
17.86 19.57 18.00
Operating Profit 6.61 7.25 7.69
OPM % 27.01% 27.03% 29.93%
0.46 0.06 0.23
Interest 0.69 0.65 0.89
Depreciation 0.48 0.56 0.66
Profit before tax 5.90 6.10 6.37
Tax % 27.63% 25.74% 33.75%
4.27 4.54 4.22
EPS in Rs 10.59 11.26 10.47
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2024 Mar 2025 Mar 2026
23.83 44.92 52.51
19.65 33.40 37.57
Operating Profit 4.18 11.52 14.94
OPM % 17.54% 25.65% 28.45%
0.41 0.58 0.29
Interest 0.94 1.45 1.54
Depreciation 0.62 0.88 1.22
Profit before tax 3.03 9.77 12.47
Tax % 28.71% 27.33% 29.75%
2.16 7.10 8.75
EPS in Rs 6.58 17.61 21.71
Dividend Payout % 0.00% 0.00% 0.00%
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: %
TTM: 17%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: %
TTM: 22%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: %
Return on Equity
10 Years: %
5 Years: %
3 Years: 38%
Last Year: 32%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2024 Mar 2025 Mar 2026
Equity Capital 3.28 4.03 4.03
Reserves 2.94 18.63 27.38
15.13 22.16 28.94
13.18 11.60 17.59
Total Liabilities 34.53 56.42 77.94
10.25 13.10 16.06
CWIP 0.03 4.62 12.85
Investments 0.03 0.03 0.03
24.22 38.67 49.00
Total Assets 34.53 56.42 77.94

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2024 Mar 2025 Mar 2026
1.02 3.39 2.78
-3.90 -9.55 -9.04
2.93 10.21 3.07
Net Cash Flow 0.05 4.05 -3.19
Free Cash Flow -2.81 -5.88 -6.43
CFO/OP 29% 36% 35%

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2024 Mar 2025 Mar 2026
Debtor Days 123.91 139.84 146.11
Inventory Days 290.31 176.30 217.51
Days Payable 129.94 98.06 119.89
Cash Conversion Cycle 284.29 218.07 243.72
Working Capital Days 28.64 70.29 74.03
ROCE % 34.18% 26.64%

Shareholding Pattern

Numbers in percentages

18 Recently
Jun 2026
64.59%
3.06%
9.08%
23.26%
No. of Shareholders 630

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

No data available.

Concalls

  • Jul 2026
    Transcript
    AI Summary
    PPT